Skip to main content

Microdosing Psychedelics as a Promising New Pharmacotherapeutic

Abstract

Microdosing psychedelics, the repeated use of small doses of substances such as psilocybin and lysergic acid diethylamide, has gained popular and scientific attention in recent years. While some users claim microdosing psychedelics has therapeutic value, to date only a handful of (placebo-controlled) experimental studies in human volunteers have been conducted testing the effects of low doses on physiological, subjective state, and performance measures. This chapter aims to answer, based on the scientific knowledge we have so far, whether microdosing psychedelics has therapeutic potential. Reviewed studies demonstrated that low doses were in general well tolerated. Single doses produced subtle, beneficial effects on selective performance measures and subjective states. The fact that most studies were conducted in small samples of healthy (young) volunteers hampers generalization to other populations. However, the observed cognitive and affective effects might be of help in some psychiatric disorders such as attention-deficit hyperactivity disorder or depression. Future placebo-controlled studies in patient populations are needed to conclude about the (therapeutic) potential of microdosing psychedelics.

Keywords

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   59.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abramson HA, Kornetsky C, Jarvik ME, Kaufman MR, Ferguson MW (1955) Lysergic acid diethylamide (Lsd-25): Xi. Content analysis of clinical reactions. J Psychol 40:53–60

    Article  Google Scholar 

  • Abramson HA, Rolo A (1965) Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects. J Asthma Res 3:81–96

    Article  CAS  PubMed  Google Scholar 

  • Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS (2019a) Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology 236:731–740

    Article  CAS  PubMed  Google Scholar 

  • Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams L-A, Hui K, Hapke E (2019b) Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J 16:43

    Article  PubMed  PubMed Central  Google Scholar 

  • Andersson M, Kjellgren A (2019) Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube. Harm Reduct J 16:63

    Article  PubMed  PubMed Central  Google Scholar 

  • Bershad AK, Preller KH, Lee R, Keedy S, Wren-Jarvis J, Bremmer MP, de Wit H (2020) Preliminary report on the effects of a low dose of LSD on resting state amygdalar functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging 5(4):461–467

    PubMed  Google Scholar 

  • Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry 86:792–800

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bertino JS Jr, Greenberg HE, Reed MD (2007) American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol 47:418+

    Article  CAS  PubMed  Google Scholar 

  • Boardman WK, Goldstone S, Lhamon WT (1957) Effects of lysergic acid diethylamide (LSD) on the time sense of Normals: a preliminary report. AMA Arch Neurol Psychiatry 78:321–324

    Article  CAS  PubMed  Google Scholar 

  • Carhart-Harris RL, Goodwin GM (2017) The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 42:2105–2113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chi T, Gold JA (2020) A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci 411:116715

    Article  CAS  PubMed  Google Scholar 

  • Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015) Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol 19:pyv072

    Article  PubMed  PubMed Central  Google Scholar 

  • Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME (2017) Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet 56:1219–1230

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC (2016) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol 6:193–213

    Article  PubMed  PubMed Central  Google Scholar 

  • Fadiman J (2017) Microdose research: without approvals, control groups, double-blinds, staff or funding by Dr James Fadiman. In.: Psychedelic Press. 2017XV. Available: https://psychedelicpress.co.uk/blogs/psychedelic-press-blog/microdose-research-james-fadiman

  • Fadiman J, Korb S (2019) Might microdosing psychedelics be safe and beneficial? An initial exploration. J Psychoactive Drugs 51:118–122

    Article  PubMed  Google Scholar 

  • Fadiman, James. 2011. The psychedelic explorer’s guide: safe, therapeutic, and sacred journeys. Rochester, Vt. Park Street Press

    Google Scholar 

  • Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2019) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237(3):841–853

    Article  PubMed  PubMed Central  Google Scholar 

  • Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M (2020) Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front Psych 10:943

    Article  Google Scholar 

  • Garner RC, Lappin G (2006) Commentary. Br J Clin Pharmacol 61:367–370

    Article  PubMed  PubMed Central  Google Scholar 

  • Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520

    Article  PubMed  PubMed Central  Google Scholar 

  • Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29:57–68

    Article  PubMed  Google Scholar 

  • Ghose T (2015) Short trip? More people ‘microdosing’ on psychedelics drugs. In Live science. https://www.nbcnews.com/science/weird-science/short-trip-more-people-microdosing-psychedelic-drugs-n390791

  • Greiner T, Burch NR, Edelberg R (1958) Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum. AMA Arch Neurol Psychiatry 79:208–210

    Article  CAS  PubMed  Google Scholar 

  • Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218:649–665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181–1197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172:145–156

    Article  CAS  PubMed  Google Scholar 

  • Horowitz M (1976) Interview with Albert Hofmann, High Times

    Google Scholar 

  • Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC (2019a) Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol 22:426–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC (2019b) Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry 10:672

    Article  PubMed  PubMed Central  Google Scholar 

  • Hutten N, Mason NL, Dolder PC, Kuypers KPC (2019c) Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psych 10:672

    Article  Google Scholar 

  • Isbell H, Belleville RE, Fraser HF, Wikler A, Logan CR (1956) Studies on lysergic acid diethylamide (LSD-25): I. Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA Arch Neurol Psychiatry 76:468–478

    Article  PubMed  Google Scholar 

  • Johnson MW, Griffiths RR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics 14:734–740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnstad PG (2018) Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Stud Alcohol Drugs 35:39–51

    Article  Google Scholar 

  • Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) Microdosing psychedelics: more questions than answers? An overview and suggestions for future research. J Psychopharmacol 33:1039–1057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lea T, Amada N, Jungaberle H, Schecke H, Klein M (2020) Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Policy 75:102600

    Article  PubMed  Google Scholar 

  • Lea T, Amada N, Jungaberle H (2019) Psychedelic microdosing: a Subreddit analysis. J Psychoactive Drugs:1–12

    Google Scholar 

  • Lee MR (2010) The history of ergot of rye (Claviceps purpurea) III: 1940–80. J R Coll Physicians Edinb 40:77–80

    Article  CAS  PubMed  Google Scholar 

  • Liechti ME (2017) Modern clinical research on LSD. Neuropsychopharmacology 42:2114–2127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44:1328–1334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mason NL, Mischler E, Uthaug MV, Kuypers KPC (2019) Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. J Psychoactive Drugs 51:123–134

    Article  PubMed  Google Scholar 

  • McGlothlin W, Cohen S, McGlothlin MS (1967) Long lasting effects of LSD on normals. Arch Gen Psychiatry 17:521–532

    Article  CAS  PubMed  Google Scholar 

  • Meaux JB, Hester C, Smith B, Shoptaw A (2006) Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J Spec Pediatr Nurs 11:214–226

    Article  PubMed  Google Scholar 

  • Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735–1740

    Article  CAS  PubMed  Google Scholar 

  • Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264–355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Osmond H (1957) A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 66:418–434

    Article  CAS  PubMed  Google Scholar 

  • Passie T (2019) The science of microdosing psychedelics. Psychedelic Press. London, UK

    Google Scholar 

  • Penn E, Tracy DK (2012) The drugs don’t work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2:179–188

    Article  PubMed  PubMed Central  Google Scholar 

  • Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH (2019) LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med 50(13):2255–2264

    Article  PubMed  Google Scholar 

  • Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX (2017) Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol 20:747–757

    Article  PubMed  PubMed Central  Google Scholar 

  • Polito V, Stevenson RJ (2019) A systematic study of microdosing psychedelics. PLoS One 14:e0211023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Predictable SEAU (2006) Side effects of antidepressants: an overview. Cleveland Clin J Med 73:351

    Article  Google Scholar 

  • Prochazkova L, Lippelt DP, Colzato LS, Kuchar M, Sjoerds Z, Hommel B (2018) Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. Psychopharmacology 235:3401–3413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sakloth F, Leggett E, Moerke MJ, Townsend EA, Banks ML, Negus SS (2019) Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Exp Clin Psychopharmacol 27:215–226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434–1452

    Article  CAS  PubMed  Google Scholar 

  • Tylš F, Páleníček T, Horáček J (2014) Psilocybin – summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24:342–356

    Article  PubMed  Google Scholar 

  • Vanderhasselt M-A, De Raedt R, De Paepe A, Aarts K, Otte G, Van Dorpe J, Pourtois G (2014) Abnormal proactive and reactive cognitive control during conflict processing in major depression. J Abnorm Psychol 123:68–80

    Article  PubMed  Google Scholar 

  • Webb M, Copes H, Hendricks PS (2019) Narrative identity, rationality, and microdosing classic psychedelics. Int J Drug Policy 70:33–39

    Article  PubMed  Google Scholar 

  • Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB (2019) The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology 236:1159–1170

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kim P. C. Kuypers .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kuypers, K.P.C. (2021). Microdosing Psychedelics as a Promising New Pharmacotherapeutic. In: Schreiber, R. (eds) Modern CNS Drug Discovery . Springer, Cham. https://doi.org/10.1007/978-3-030-62351-7_18

Download citation

Publish with us

Policies and ethics